V 2021

An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

TAYLOR, Joe, Bridget SHAW and Al. ET

Basic information

Original name

An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

Authors

TAYLOR, Joe (guarantor), Bridget SHAW and Al. ET

Edition

NA. London, 29 pp. NA, 2021

Publisher

Far-RMS

Other information

Language

English

Type of outcome

Výzkumná zpráva

Field of Study

30230 Other clinical medicine subjects

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/21:00124333

Organization unit

Faculty of Medicine

Keywords (in Czech)

relapsed rhabdomyosarcoma; children; clinical study; FaR-RMS

Keywords in English

relapsed rhabdomyosarcoma; children; clinical study; FaR-RMS

Tags

Tags

International impact
Změněno: 1/3/2022 12:57, Bc. Hana Vladíková, BBA

Abstract

V originále

FaR-RMS is an over-arching study for patients with newly diagnosed and relapsed RMS including multi-arm, multi-stage questions with three principal aims. These are to evaluate:•systemic therapy through the introduction of new agent regimens in the most advanced disease states: Very High Risk (VHR), High Risk (HR) and Relapse•the duration of maintenance therapy•radiotherapy to improve local control in VHR, HR and Standard Risk (SR) patients and to treat metastatic diseaseIn addition the study will evaluate:•risk stratification through the use of PAX-FOXO1 fusion gene status instead of histological subtyping•the use of FDG PET-CT response assessment as a prognostic biomarker for outcome following induction chemotherapy FaR-RMS includes a study entry point where all patients with RMS may give consent for the analysis of their biological samples and tumour pathology, alongside the collection of very basic patient characteristics, a treatment summary, and follow-up data for events.

Links

90128, large research infrastructures
Name: CZECRIN III